跳至主要内容
临床试验/JPRN-UMIN000008807
JPRN-UMIN000008807已完成1 期

A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients with Advanced Solid Malignancies - A Phase 1 study of ZSTK474 in Japanese Patients with Advanced Solid Malignancies

Zenyaku Kogyo Co., Ltd.0 个研究点目标入组 30 人开始时间: 2012年8月31日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Have received any investigational agents within the 4 weeks prior to the start of dosing with ZSTK474; 2.Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor; 3.Have serious or significant intercurrent illnesses or underlying diseases, including, but not limited to: a.History of diabetes b.Hepatic c.Renal d.Cardiovascular e.Others 4.Patients who are participating in the other clinical study or at the time of informed consent of this study.

研究者

相似试验